Dr. Oh on AR-Targeted Therapy and Chemotherapy for CRPC

William K. Oh, MD
Published: Friday, Jun 02, 2017



William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses AR-targeted therapy and chemotherapy for poor prognostic patients with castration-resistant prostate cancer.

Patients who receive chemotherapy after AR-targeted therapy seem to see better results, states Oh. Initially, these patients were intrinsically sicker and had worse prognostic factors

The patients with the most systemic types of CRPC will not respond to a second AR-targeted therapy and will potentially see a survival benefit if they receive chemotherapy.
 


William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses AR-targeted therapy and chemotherapy for poor prognostic patients with castration-resistant prostate cancer.

Patients who receive chemotherapy after AR-targeted therapy seem to see better results, states Oh. Initially, these patients were intrinsically sicker and had worse prognostic factors

The patients with the most systemic types of CRPC will not respond to a second AR-targeted therapy and will potentially see a survival benefit if they receive chemotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x